PTC Therapeutics, Inc. (PTCT)
$
49.59
-0.21 (-0.42%)
Key metrics
Financial statements
Free cash flow per share
9.5901
Market cap
3.9 Billion
Price to sales ratio
2.2320
Debt to equity
-1.8793
Current ratio
3.6203
Income quality
1.1202
Average inventory
27.9 Million
ROE
-0.9890
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
PTC Therapeutics, Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of medicines for patients with rare disorders. Its portfolio includes a range of commercial products and candidates at various development stages, focusing on therapeutic areas such as rare diseases. The company’s offerings, including Translarna and Emflaza, serve patients with Duchenne muscular dystrophy in the European Economic Area and the United States, and address nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. Additionally, PTC Therapeutics commercializes Tegsedi and Waylivra for rare diseases in Latin America and the Caribbean, while Evrysdi is marketed for spinal muscular atrophy treatment in individuals aged two months and older in Brazil. The firm's innovative splicing platform features PTC518, currently being developed for Huntington's disease. The diluted EPS is -$4.73 accounting for potential share dilution. The net total of other income and expenses is -$60,549,000.00 reflecting non-core financial activities. The weighted average number of shares outstanding is $76,845,055.00 highlighting the company's shareholder base. The company's stock is identified with the symbol '$PTCT' in the market, and the financial data pertains to the fiscal year $2024. PTC Therapeutics maintains collaborations with notable entities such as F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to further drug discovery and development research in regenerative medicine, along with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra. At an affordable price of $49.46 the stock is suitable for budget-conscious investors. With an average trading volume of $1,176,112.00 the stock indicates moderate liquidity, providing investors ease of entry and exit. The company possesses a mid-range market capitalization of $3,939,335,379.00 positioning it as a steady performer within the biopharmaceutical landscape. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, PTC Therapeutics belongs to the Healthcare sector, driving both innovation and growth in therapeutic development.
Is PTC Therapeutics, Inc. (PTCT) a good investment?
Investing in PTC Therapeutics, Inc. (PTCT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is PTC Therapeutics, Inc. (PTCT)'s stock forecast?
Analysts predict PTC Therapeutics, Inc. stock to fluctuate between $30.41 (low) and $58.38 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is PTC Therapeutics, Inc.'s market capitalization?
As of 2025-08-20, PTC Therapeutics, Inc.'s market cap is $3,939,335,379, based on 79,438,100 outstanding shares.
How does PTC Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., PTC Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy PTC Therapeutics, Inc. (PTCT) stock?
To buy PTC Therapeutics, Inc. (PTCT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for PTCT. Place an order (Market, Limit, etc.).
What is the best time to invest in PTC Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did PTC Therapeutics, Inc. perform in the last earnings report?
Revenue: $806,780,000 | EPS: -$4.73 | Growth: -43.49%.
Where can I find PTC Therapeutics, Inc.'s investor relations reports?
Visit https://www.ptcbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for PTC Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for PTC Therapeutics, Inc. stock?
All-time high: $59.84 (2023-05-22) | All-time low: $17.53 (2023-11-02).
What are the key trends affecting PTC Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Ellen Cavaleri - Corporate Participant Eric Pauwels - Chief Business Officer Jarwei Fang - Corporate Participant Matthew B. Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Dingding Shi - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jenny Leigh Gonzalez-Armenta - Leerink Partners LLC, Research Division John Peyton Bohnsack - TD Cowen, Research Division Joon So Lee - Truist Securities, Inc., Research Division Judah C.
zacks.com
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $1.16 per share a year ago.
prnewswire.com
LOS ANGELES , June 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ: PTCT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
prnewswire.com
– Broad label inclusive of all ages and disease severities – – Launch to be initiated in Germany – WARREN, N.J. , June 23, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Sephience™ (sepiapterin) was granted marketing authorization by the European Commission for the treatment of children and adults living with phenylketonuria (PKU).
businesswire.com
LOS ANGELES--(BUSINESS WIRE)---- $PTCT--PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
zacks.com
PTC Therapeutics (PTCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PTC Therapeutics, Inc. ("PTC Therapeutics, Inc.") (NASDAQ:PTCT) concerning possible violations of federal securities laws. PTC issued a press release on May 5, 2025, "announc[ing] results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
See all news
